The Use of H 2 ‐Receptor Antagonist in the Treatment of Peptic Ulcer Disease in Children

P. K. H. Tam,H. Saing

DOI: https://doi.org/10.1002/j.1536-4801.1989.tb09699.x

2024-01-04

Journal of Pediatric Gastroenterology and Nutrition

Abstract:We report our 20 years' experience on the management of 78 children with primary chronic peptic ulcer, giving special emphasis to the recent 32 patients (29 duodenal ulcer, 3 gastric ulcer) who received H 2 ‐antagonist therapy guided by endoscopic surveillance. The most striking observation was the marked decrease in the incidence of "failed medical treatment necessitating surgery" from 34.8% (16/46) in the pre‐H 2 ‐antagonist era to 3.1% (1/32) in the H 2 ‐antagonist era. H 2 antagonist was uniformly well tolerated and without side‐effects. In 29 patients with duodenal ulcer, a 6‐week therapeutic course resulted in complete ulcer healing in 22 (75.9%). Further therapeutic courses resulted in complete ulcer healing in four additional patients (13.8%). There was only partial ulcer healing in two patients (6.9%) and nonhealing in one patient (3.49%). There were 11 episodes of recurrence in nine patients (symptomatic 5, asymptomatic 6). Recurrence was more frequent when nocturnal‐dose maintanence was not given (8/11 recurrences). All recurrences responded satisfactorily to further H 2 ‐antagonist therapy. Patients with gastric ulcer responded even more favorably, all three healing completely with a single therapeutic course and not requiring maintenance therapy. We conclude that H 2 ‐antagonist is safe and highly effective for healing peptic ulcer in children. For duodenal ulcer, maintenance therapy ensures a satisfactory remission rate.

pediatrics,gastroenterology & hepatology,nutrition & dietetics